Key result
Natural polyphenols demonstrate therapeutic potential in preclinical models of diabetic cardiomyopathy by mitigating oxidative stress, inflammation, and extracellular matrix remodeling.
Why the study?
Diabetic cardiomyopathy is a prime cause of fatality with diagnosis and treatment challenges, requiring a better understanding of cellular pathophysiology to reveal therapeutic targets and prevent disease progression.
This review highlights the therapeutic potential of natural polyphenols in managing diabetic cardiomyopathy based on preclinical evidence.
Preclinical data on polyphenols in diabetic cardiomyopathy remain hypothesis-generating; human trials needed before clinical consideration.
Diabetic cardiomyopathy (DCM) is an outcome of disturbances in metabolic activities through oxidative stress, local inflammation, and fibrosis, as well as a prime cause of fatality worldwide. Cardiovascular disorders in diabetic individuals have become a challenge in diagnosis and formulation of treatment prototype. It is necessary to have a better understanding of cellular pathophysiology that reveal the therapeutic targets and prevent the progression of cardiovascular diseases due to hyperglycemia. Critical changes in levels of collagen and integrin have been observed in the extracellular matrix of heart, which was responsible for cardiac remodeling in diabetic patients. This review explored the understanding of the mechanisms of how the phytochemicals provide cardioprotection under diabetes along with the caveats and provide future perspectives on these agents as prototypes for the development of drugs for managing DCM. Thus, here we summarized the effect of various plant extracts and natural polyphenols tested in preclinical and cell culture models of diabetic cardiomyopathy. Further, the potential use of selected polyphenols that improved the therapeutic efficacy against diabetic cardiomyopathy is also illustrated.
No takes yet. Share an insight, caveat, or question.
Atale et al. (2020) conducted a review in Diabetic cardiomyopathy. Natural polyphenols was evaluated. Natural polyphenols demonstrate therapeutic potential in preclinical models of diabetic cardiomyopathy by mitigating oxidative stress, inflammation, and extracellular matrix remodeling.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: